Healthcare staff, people aged above 65 will be given priority for COVID vaccine: Harsh Vardhan
[ad_1]
Noting that it’s pure to prioritise COVID-19 vaccine distribution, Health Minister Harsh Vardhan on Thursday mentioned healthcare staff and people aged above 65 will be early recipients when a vaccine turns into accessible.
Addressing a webinar organised by the FICCI FLO on ‘The Shifting Healthcare Paradigm During and Post-Covid’, Mr. Vardhan mentioned COVID-19 vaccine will be accessible within the subsequent few months and it’s estimated that by July-August 400-500 million doses will be made accessible for 25-30 crore people.
“It is natural the vaccine distribution would have to be prioritised. As you know the healthcare workers who are corona warriors they will be prioritised, then people who are above 65 years of age they have been prioritised, then those from 50-65 years of age have been prioritised,” he mentioned.
“Then those below 50 years who have other diseases. It is all being decided by experts with a scientific point of view. We have made a very detailed, meticulous plan on this. What we would have to do in March-April next year, we have started planning for it from now only,” Mr. Vardhan added.
The minister mentioned one can defend oneself from this lethal virus with small precautions like carrying a very good high quality masks correctly, sustaining social distance and taking good care of hand-hygiene.
India’s coronavirus caseload mounted to 89,58,483 on Thursday with 45,576 infections being reported in a day, whereas the dying toll climbed to 1,31,578 with 585 new fatalities.
The phase-3 trial of the Oxford vaccine of the Serum Institute is nearly close to completion, whereas the phase-3 medical trial of the indigenously-developed vaccine candidate of the Bharat Biotech and the Indian Council of Medical Research (ICMR) has already began.
Dr Reddy’s Laboratories will quickly begin the mixed phase-2 and phase-3 medical trials of the Russian COVID-19 vaccine, Sputnik V, in India. Also, the Biological E Limited has began early phases 1 and a pair of human trials of its COVID-19 vaccine candidate.
Pfizer Inc. and BioNTech SE mentioned their vaccine candidate was discovered to be greater than 95% efficient in stopping COVID-19, whereas Moderna on Monday mentioned its vaccine candidate in opposition to COVID-19 discovered it to have an efficacy of 94.5%.
[ad_2]
